Drug Trial Radar · NCT05658510
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Nov 21, 2022
Primary completion
Aug 15, 2025
Study completion Aug 15, 2025
Sponsor
- Lead sponsor
- BioXcel Therapeutics IncIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Dec 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.
Conditions
- Agitation,Psychomotor
- Bipolar I Disorder
- Bipolar II Disorder
- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorders
Interventions
BXCL501Drug
Sublingual Film
Matching PlaceboDrug
Sublingual Placebo Film
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total scoreTime frame: 2 hours
- Part 2: The incidence of SAEs and TEAEs compared with placebo.Time frame: Through study completion, an average of 12 weeks
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
BioXcel Clinical Research Site 113
Bellflower, California
BioXcel Clinical Research Site 128
Cerritos, California
BioXcel Clinical Research Site 110
Culver City, California
BioXcel Clinical Research Site 108
Garden Grove, California
BioXcel Clinical Research Site 117
Lemon Grove, California
BioXcel Clinical Research Site 121
Los Angeles, California
BioXcel Clinical Research Site 123
Oceanside, California
BioXcel Clinical Research Site 104
Orange, California
BioXcel Clinical Research Site 133
Rancho Cucamonga, California
BioXcel Clinical Research Site 114
Riverside, California
BioXcel Clinical Research Site 129
Denver, Colorado
BioXcel Clinical Research Site 131
Miami, Florida
BioXcel Clinical Research Site 124
Miami, Florida
BioXcel Clinical Research Site 130
Elgin, Illinois
BioXcel Clinical Research Site 103
Gaithersburg, Maryland
BioXcel Clinical Research Site 118
Las Vegas, Nevada
BioXcel Clinical Research Site 137
Las Vegas, Nevada
BioXcel Clinical Research Site 105
Berlin, New Jersey
BioXcel Clinical Research Site 122
Beachwood, Ohio
BioXcel Clinical Research Site 136
Austin, Texas
BioXcel Clinical Research Site 102
DeSoto, Texas
BioXcel Clinical Research Site 125
Irving, Texas
BioXcel Clinical Research Site 127
Plano, Texas
BioXcel Clinical Research Site 126
Everett, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.